Closure of Trading Window
A meeting of the Board of Directors is scheduled to be held on May 16, 2017 to consider and approve Audited Standalone and Consolidated Financials for the Quarter and Year ended March 31, 2017. In view of the above and pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and as per Company's Code of Conduct to regulate, monitor and report trading by insiders, the trading window for dealing in the securities of the Company shall... Shareholding for the Period Ended March 31, 2017
Amrutanjan Health Care Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here Compliance Certificate Under Reg 7(3)By RTA & Compliance Officer For The Half Year Ended March 31, 2017
Compliance Certificate under reg 7(3)by RTA & Compliance Officer for the half year ended March 31, 2017 PCS Certificate Under 40(10) For Transfer/ Transmission/ Transportation
The Company is attaching herewith the PCS certificate under 40(10) for Transfer/ Transmission/ Transportation for the half year ended March 31, 2017. Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2017
Amrutanjan Health Care Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2017, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Outcome of Board Meeting - Modified Scheme of Amalgamation
Amrutanjan Health Care Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 09, 2017 had inter-alia approved the modified/ altered Scheme of Merger of the Wholly Owned Subsidiary, M/s. Amrutanjan Pharmaessense Private Limited with the Parent Company, M/s. Amrutanjan Health Care Limited. Board declares Second Interim Dividend
Amrutanjan Health Care Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 09, 2017, had inter-alia:1. Declared 2nd Interim Dividend of Rs. 1.10/- per share for 1the year 2016-2017 on the Equity Shares of the Company.2. Approved the modified / altered Scheme of merger of the Wholly Owned Subsidiary, M/s. Amrutanjan Pharmaessense Private Limited with M/s. Amrutanjan Health Care Limited. Standalone Financial Results, Limited Review Report, Results Press Release for December 31, 2016
Amrutanjan Health Care Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20162. Standalone Limited Review for the period ended December 31, 20163. Result Press Release for the period ended December 31, 2016 Fixes Record Date for Interim Dividend
Amrutanjan Health Care Ltd has informed BSE that the Company has fixed February 17, 2017 as the Record Date for the purpose of Payment of Interim Dividend, if approved. Board to consider Second Interim Dividend
Amrutanjan Health Care Ltd has informed BSE that a meeting of the Board of Directors is scheduled to be held on February 09, 2017, inter alia, to consider and approve the following:1. Un-audited Standalone Financial Results along with the Limited Review Report for the quarter and nine months ended December 31, 2016.2. Declaration of 2nd interim dividend for the financial year 2016-17...